Track the REGENERON PHARMACEUTICALS INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €78.5bn. The latest transaction was filed on 14 January 2016 (Acquisition). Among the most active insiders: Sanofi. Every trade is free.
20
Insider Decl.
n/a
Thresholds
n/a
18 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate REGENERON PHARMACEUTICALS INC Buy (bullish), based on 27 analysts. Average price target: US$833.54.
Fundamental score
Ranked 3,669 of 29,062 companies
71.6
score / 100
Value
58
Quality
85
FCF yld4.8%
Earn yld5.7%
EV/EBITDA14.0x
ROE14%
Gross mgn85%
Net mgn31%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
REGENERON PHARMACEUTICALS INC is an American biopharmaceutical company focused on the research, development, and commercialization of medicines for serious diseases. It is listed on NASDAQ under the symbol REGN.